Latest filing published 12 Aug 2021 for Fulcrum Therapeutics, Inc., €139k.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Christopher Moxham: trading record in brief
All filings by Christopher Moxham on record concern Fulcrum Therapeutics, Inc., in the capacity of senior executive. In total, 4 filings cover trades dated 10 August 2021.
The open-market record consists of 2 sales worth €777k, with no purchase. Besides market trades, the filings include 2 option exercises.
Most recently, on 12 August 2021, the filings show an open-market sale worth €300k in Fulcrum Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Christopher Moxham
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 20,714 shares@ US$7.84100.0% of flowCommon StockSEC:0000899243-21-032755:0
1 of 1 declaration
